| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 12 | -1,340,469 | 100% | $199.93 | -$267,995,417 |
| Net | -12 | -1,340,469 | -100% | -$267,995,417 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Matthew Rabinowitz | EXECUTIVE CHAIRMAN, Director | $458,632,895 | -$66,950,225 | -13% | 12 Mar 2026 |
| Roelof Botha | Director | $264,997,107 | -$17,708,936 | -6.3% | 30 Jan 2026 |
| James Healy | Director | $225,766,720 | 25 Apr 2025 | ||
| Jonathan Sheena | Director, CO-FOUNDER | $62,722,816 | -$16,862,745 | -21% | 09 Mar 2026 |
| Daniel Rabinowitz | Sec. And Chief Legal Officer | $47,988,038 | -$12,373,871 | -20% | 09 Mar 2026 |
| John Fesko | President, Chief Bus. Officer | $38,621,702 | -$6,961,987 | -15% | 09 Mar 2026 |
| Steven Leonard Chapman | CEO AND PRESIDENT, Director | $34,563,373 | -$90,975,747 | -72% | 09 Mar 2026 |
| Solomon Moshkevich | President, Clinicaldiagnostics | $30,799,950 | -$15,794,610 | -34% | 09 Mar 2026 |
| Michael Burkes Brophy | Chief Financial Officer | $13,821,871 | -$22,098,749 | -62% | 09 Mar 2026 |
| Robert Alan Schueren | Chief Operating Officer | $9,082,035 | 27 Jan 2023 | ||
| Herm Rosenman | Director | $4,682,828 | -$11,011,477 | -70% | 30 Jan 2026 |
| Roy D. Baynes | Director | $4,221,899 | -$2,809,689 | -40% | 30 Jan 2026 |
| Gail Boxer Marcus | Director | $1,548,587 | -$2,903,422 | -65% | 30 Jan 2026 |
| Brinkley Ruth Williams | Director | $1,234,566 | 30 Jan 2026 | ||
| Monica Bertagnolli | Director | $1,212,115 | 30 Jan 2026 | ||
| Rowan E. Chapman | Director | $1,100,817 | -$1,543,960 | -58% | 13 Mar 2026 |
| Todd C. Cozzens | Director | $1,038,936 | 25 May 2022 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Matthew Rabinowitz | NTRA | Common Stock | Sale | -2.12% | $9,813,883 | $196.28 | -50,000 | 2,310,772 | 16 Mar 2026 | Direct |
| Matthew Rabinowitz | NTRA | Common Stock | Options Exercise | 2.16% | 50,000 | 2,360,772 | 16 Mar 2026 | Direct | ||
| Matthew Rabinowitz | NTRA | Stock Option (right to buy) | Options Exercise | -33.3% | -50,000 | 100,000 | 16 Mar 2026 | Direct | ||
| Rowan E. Chapman | NTRA | Common Stock | Sale | -2.08% | $23,348 | $191.38 | -122 | 5,752 | 13 Mar 2026 | Direct |
| Matthew Rabinowitz | NTRA | Common Stock | Sale | -3.14% | $14,175,379 | $189.01 | -75,000 | 2,310,772 | 13 Mar 2026 | Direct |
| Matthew Rabinowitz | NTRA | Common Stock | Options Exercise | 3.25% | 75,000 | 2,385,772 | 13 Mar 2026 | Direct | ||
| Matthew Rabinowitz | NTRA | Stock Option (right to buy) | Options Exercise | -33.3% | -75,000 | 150,000 | 13 Mar 2026 | Direct | ||
| Matthew Rabinowitz | NTRA | Common Stock | Sale | -3.14% | $14,294,119 | $190.59 | -75,000 | 2,310,772 | 12 Mar 2026 | Direct |
| Matthew Rabinowitz | NTRA | Common Stock | Options Exercise | 3.25% | 75,000 | 2,385,772 | 12 Mar 2026 | Direct | ||
| Matthew Rabinowitz | NTRA | Stock Option (right to buy) | Options Exercise | -25% | -75,000 | 225,000 | 12 Mar 2026 | Direct | ||
| Michael Burkes Brophy | NTRA | Common Stock | Sale | -1.22% | $160,244 | $204.13 | -785 | 63,354 | 10 Mar 2026 | Direct |
| Steven Leonard Chapman | NTRA | Common Stock | Sale | -3.47% | $1,147,838 | $204.13 | -5,623 | 156,607 | 10 Mar 2026 | Direct |
| Daniel Rabinowitz | NTRA | Common Stock | Sale | -0.74% | $356,212 | $204.13 | -1,745 | 233,285 | 10 Mar 2026 | Direct |
| Jonathan Sheena | NTRA | Common Stock | Sale | -0.05% | $25,925 | $204.13 | -127 | 262,325 | 10 Mar 2026 | Direct |
| John Fesko | NTRA | Common Stock | Sale | -0.37% | $144,322 | $204.13 | -707 | 189,199 | 10 Mar 2026 | Direct |
| Solomon Moshkevich | NTRA | Common Stock | Sale | -0.6% | $186,781 | $204.13 | -915 | 150,882 | 10 Mar 2026 | Direct |
| Michael Burkes Brophy | NTRA | Common Stock | Award | 3.17% | 1,968 | 64,139 | 09 Mar 2026 | Direct | ||
| Steven Leonard Chapman | NTRA | Common Stock | Award | 3.59% | 5,623 | 162,230 | 09 Mar 2026 | Direct | ||
| Daniel Rabinowitz | NTRA | Common Stock | Award | 0.75% | 1,745 | 235,030 | 09 Mar 2026 | Direct | ||
| Jonathan Sheena | NTRA | Common Stock | Award | 0.1% | 258 | 262,452 | 09 Mar 2026 | Direct | ||
| John Fesko | NTRA | Common Stock | Award | 0.94% | 1,774 | 189,906 | 09 Mar 2026 | Direct | ||
| Solomon Moshkevich | NTRA | Common Stock | Award | 1.18% | 1,774 | 151,797 | 09 Mar 2026 | Direct | ||
| Daniel Rabinowitz | NTRA | Common Stock | Sale | -3.47% | $1,646,696 | $196.08 | -8,398 | 233,285 | 06 Mar 2026 | Direct |
| Daniel Rabinowitz | NTRA | Common Stock | Options Exercise | 2.37% | 5,598 | 241,683 | 06 Mar 2026 | Direct | ||
| Daniel Rabinowitz | NTRA | Stock Option (Right to Buy) | Options Exercise | -100% | -5,598 | 0 | 06 Mar 2026 | Direct | ||
| Jonathan Sheena | NTRA | Common Stock | Sale | -1.16% | $614,710 | $200.23 | -3,070 | 262,194 | 02 Mar 2026 | Direct |
| Steven Leonard Chapman | NTRA | Common Stock | Sale | -2.46% | $790,095 | $200.02 | -3,950 | 156,607 | 02 Mar 2026 | Direct |
| Solomon Moshkevich | NTRA | Common Stock | Sale | -1.96% | $599,545 | $199.85 | -3,000 | 150,023 | 02 Mar 2026 | Direct |
| Solomon Moshkevich | NTRA | Common Stock | Options Exercise | 3.47% | 5,125 | 153,023 | 02 Mar 2026 | Direct | ||
| Solomon Moshkevich | NTRA | Stock Option (right to buy) | Options Exercise | -100% | -5,125 | 0 | 02 Mar 2026 | Direct | ||
| Jonathan Sheena | NTRA | Common Stock | Award | 0.8% | 2,103 | 265,264 | 27 Feb 2026 | Direct | ||
| Steven Leonard Chapman | NTRA | Common Stock | Award | 30.4% | 37,401 | 160,557 | 27 Feb 2026 | Direct | ||
| Solomon Moshkevich | NTRA | Common Stock | Award | 7.29% | 10,051 | 147,898 | 27 Feb 2026 | Direct | ||
| Matthew Rabinowitz | NTRA | Common Stock | Award | 1.31% | 29,920 | 2,310,772 | 27 Feb 2026 | Direct | ||
| Daniel Rabinowitz | NTRA | Common Stock | Award | 5.48% | 12,272 | 236,085 | 27 Feb 2026 | Direct | ||
| John Fesko | NTRA | Common Stock | Award | 5.64% | 10,051 | 188,132 | 27 Feb 2026 | Direct | ||
| Michael Burkes Brophy | NTRA | Common Stock | Award | 19.3% | 10,051 | 62,171 | 27 Feb 2026 | Direct | ||
| John Fesko | NTRA | Common Stock | Sale | -1.98% | $830,279 | $231.02 | -3,594 | 178,081 | 03 Feb 2026 | Direct |
| Solomon Moshkevich | NTRA | Common Stock | Sale | -1.18% | $378,229 | $230.77 | -1,639 | 137,847 | 03 Feb 2026 | Direct |
| Daniel Rabinowitz | NTRA | Common Stock | Sale | -0.59% | $307,845 | $230.77 | -1,334 | 223,813 | 03 Feb 2026 | Direct |
| Steven Leonard Chapman | NTRA | Common Stock | Sale | -3.69% | $1,090,379 | $230.77 | -4,725 | 123,156 | 03 Feb 2026 | Direct |
| Michael Burkes Brophy | NTRA | Common Stock | Sale | -11.8% | $1,580,926 | $227.83 | -6,939 | 52,120 | 03 Feb 2026 | Direct |
| Jonathan Sheena | NTRA | Common Stock | Sale | -0.17% | $100,384 | $230.77 | -435 | 263,161 | 03 Feb 2026 | Direct |
| Solomon Moshkevich | NTRA | Common Stock | Sale | -2.11% | $694,309 | $231.44 | -3,000 | 139,486 | 02 Feb 2026 | Direct |
| Steven Leonard Chapman | NTRA | Common Stock | Sale | -40% | $19,680,040 | $230.72 | -85,299 | 127,881 | 02 Feb 2026 | Direct |
| John Fesko | NTRA | Common Stock | Award | 3.49% | 6,135 | 181,675 | 30 Jan 2026 | Direct | ||
| Rowan E. Chapman | NTRA | Common Stock | Award | 1.68% | 97 | 5,874 | 30 Jan 2026 | Direct | ||
| Monica Bertagnolli | NTRA | Common Stock | Award | 1.34% | 70 | 5,291 | 30 Jan 2026 | Direct | ||
| Gail Boxer Marcus | NTRA | Common Stock | Award | 1.58% | 91 | 5,853 | 30 Jan 2026 | Direct | ||
| Roy D. Baynes | NTRA | Common Stock | Award | 0.38% | 70 | 18,429 | 30 Jan 2026 | Direct |